GlassScriptPhysician profile
Dipesh Maan
NPI 1255773784
$1,572.24
in general payments reported to CMS, 2019-2025
23 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $20.66 · 2021: $201 · 2022: $336 · 2023: $157 · 2024: $250 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $258.26 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $224.76 | 2019-2022 | |
| Travere Therapeutics, INC. | $217.71 | 2023-2025 | |
| Medtronic, INC. | $144.83 | 2025 | Corevalve Evolut R |
| Amgen INC. | $105.77 | 2020-2025 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $79.55 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.52 | 2023-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $63.24 | 2021-2025 | Jynarque, Voyxact |
| Bard Peripheral Vascular, INC. | $59.13 | 2022 | |
| Fresenius USA Marketing, INC. | $44.17 | 2019-2022 | |
| Glaxosmithkline, LLC. | $40.45 | 2021-2023 | Benlysta |
| Baxter Healthcare | $33.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.09 | 2021-2024 | |
| Akebia Therapeutics INC | $28.14 | 2019-2024 | Vafseo |
| Mallinckrodt Hospital Products INC. | $22.35 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $21.53 | 2019 | |
| Genzyme Corporation | $19.61 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.98 | 2022 | |
| Lilly USA, LLC | $18.34 | 2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $17.01 | 2023 | Keveyis |
| Calliditas Therapeutics US INC. | $16.51 | 2022 | |
| Daiichi Sankyo INC. | $16.49 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipesh Maan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.